Logo image of MNKD

MANNKIND CORP (MNKD) Stock Fundamental Analysis

NASDAQ:MNKD - Nasdaq - US56400P7069 - Common Stock - Currency: USD

4.74  +0.07 (+1.5%)

After market: 4.6 -0.14 (-2.95%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to MNKD. MNKD was compared to 567 industry peers in the Biotechnology industry. MNKD has an average financial health and profitability rating. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year MNKD was profitable.
In the past year MNKD had a positive cash flow from operations.
MNKD had negative earnings in 4 of the past 5 years.
In multiple years MNKD reported negative operating cash flow during the last 5 years.
MNKD Yearly Net Income VS EBIT VS OCF VS FCFMNKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M -300M

1.2 Ratios

With an excellent Return On Assets value of 7.00%, MNKD belongs to the best of the industry, outperforming 94.71% of the companies in the same industry.
With an excellent Return On Invested Capital value of 20.74%, MNKD belongs to the best of the industry, outperforming 98.24% of the companies in the same industry.
Industry RankSector Rank
ROA 7%
ROE N/A
ROIC 20.74%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MNKD Yearly ROA, ROE, ROICMNKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

MNKD has a better Profit Margin (9.66%) than 93.65% of its industry peers.
MNKD has a Operating Margin of 25.07%. This is amongst the best in the industry. MNKD outperforms 96.83% of its industry peers.
MNKD has a Gross Margin of 74.19%. This is amongst the best in the industry. MNKD outperforms 82.72% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 25.07%
PM (TTM) 9.66%
GM 74.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
MNKD Yearly Profit, Operating, Gross MarginsMNKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
The number of shares outstanding for MNKD has been increased compared to 1 year ago.
Compared to 5 years ago, MNKD has more shares outstanding
The debt/assets ratio for MNKD has been reduced compared to a year ago.
MNKD Yearly Shares OutstandingMNKD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
MNKD Yearly Total Debt VS Total AssetsMNKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

MNKD has an Altman-Z score of -7.66. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -7.66, MNKD is not doing good in the industry: 69.14% of the companies in the same industry are doing better.
MNKD has a debt to FCF ratio of 8.83. This is a slightly negative value and a sign of low solvency as MNKD would need 8.83 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 8.83, MNKD belongs to the best of the industry, outperforming 92.95% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.83
Altman-Z -7.66
ROIC/WACC2.08
WACC9.99%
MNKD Yearly LT Debt VS Equity VS FCFMNKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

MNKD has a Current Ratio of 3.28. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MNKD (3.28) is worse than 62.43% of its industry peers.
MNKD has a Quick Ratio of 2.94. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
MNKD's Quick ratio of 2.94 is on the low side compared to the rest of the industry. MNKD is outperformed by 63.67% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 2.94
MNKD Yearly Current Assets VS Current LiabilitesMNKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 260.00%, which is quite impressive.
The Revenue has grown by 43.49% in the past year. This is a very strong growth!
Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%390.38%
Revenue 1Y (TTM)43.49%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%31.3%

3.2 Future

MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.66% yearly.
The Revenue is expected to grow by 14.37% on average over the next years. This is quite good.
EPS Next Y133.15%
EPS Next 2Y82.07%
EPS Next 3Y58.67%
EPS Next 5Y43.66%
Revenue Next Year13.64%
Revenue Next 2Y14.1%
Revenue Next 3Y12.72%
Revenue Next 5Y14.37%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MNKD Yearly Revenue VS EstimatesMNKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
MNKD Yearly EPS VS EstimatesMNKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 59.25 indicates a quite expensive valuation of MNKD.
Based on the Price/Earnings ratio, MNKD is valued cheaper than 92.95% of the companies in the same industry.
MNKD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.79.
With a Price/Forward Earnings ratio of 25.41, MNKD can be considered very expensive at the moment.
MNKD's Price/Forward Earnings ratio is rather cheap when compared to the industry. MNKD is cheaper than 93.30% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.38. MNKD is around the same levels.
Industry RankSector Rank
PE 59.25
Fwd PE 25.41
MNKD Price Earnings VS Forward Price EarningsMNKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 94.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 43.89
EV/EBITDA 17.5
MNKD Per share dataMNKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

MNKD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MNKD's earnings are expected to grow with 58.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.44
PEG (5Y)N/A
EPS Next 2Y82.07%
EPS Next 3Y58.67%

More info and screens

0

5. Dividend

5.1 Amount

MNKD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANNKIND CORP

NASDAQ:MNKD (4/25/2025, 8:24:20 PM)

After market: 4.6 -0.14 (-2.95%)

4.74

+0.07 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners61.62%
Inst Owner Change-57.87%
Ins Owners1.42%
Ins Owner Change1.03%
Market Cap1.44B
Analysts86.67
Price Target10.49 (121.31%)
Short Float %9.59%
Short Ratio13.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.47%
Min EPS beat(2)-34.64%
Max EPS beat(2)-18.3%
EPS beat(4)1
Avg EPS beat(4)-62.27%
Min EPS beat(4)-246.98%
Max EPS beat(4)50.83%
EPS beat(8)4
Avg EPS beat(8)-14.92%
EPS beat(12)5
Avg EPS beat(12)-9.48%
EPS beat(16)6
Avg EPS beat(16)-8.92%
Revenue beat(2)1
Avg Revenue beat(2)-3.7%
Min Revenue beat(2)-7.78%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)2.37%
Min Revenue beat(4)-7.78%
Max Revenue beat(4)9.49%
Revenue beat(8)6
Avg Revenue beat(8)4.13%
Revenue beat(12)9
Avg Revenue beat(12)7.39%
Revenue beat(16)12
Avg Revenue beat(16)6.84%
PT rev (1m)2.86%
PT rev (3m)9.23%
EPS NQ rev (1m)3.53%
EPS NQ rev (3m)46.67%
EPS NY rev (1m)1.59%
EPS NY rev (3m)-16.88%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)-0.38%
Revenue NY rev (3m)-4.97%
Valuation
Industry RankSector Rank
PE 59.25
Fwd PE 25.41
P/S 5.04
P/FCF 43.89
P/OCF 33.88
P/B N/A
P/tB N/A
EV/EBITDA 17.5
EPS(TTM)0.08
EY1.69%
EPS(NY)0.19
Fwd EY3.93%
FCF(TTM)0.11
FCFY2.28%
OCF(TTM)0.14
OCFY2.95%
SpS0.94
BVpS-0.26
TBVpS-0.28
PEG (NY)0.44
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7%
ROE N/A
ROCE 22.94%
ROIC 20.74%
ROICexc 56.39%
ROICexgc 60.16%
OM 25.07%
PM (TTM) 9.66%
GM 74.19%
FCFM 11.49%
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 8.83
Debt/EBITDA 3.39
Cap/Depr 131.5%
Cap/Sales 3.4%
Interest Coverage 4.09
Cash Conversion 53.84%
Profit Quality 118.96%
Current Ratio 3.28
Quick Ratio 2.94
Altman-Z -7.66
F-Score8
WACC9.99%
ROIC/WACC2.08
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%390.38%
EPS Next Y133.15%
EPS Next 2Y82.07%
EPS Next 3Y58.67%
EPS Next 5Y43.66%
Revenue 1Y (TTM)43.49%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%31.3%
Revenue Next Year13.64%
Revenue Next 2Y14.1%
Revenue Next 3Y12.72%
Revenue Next 5Y14.37%
EBIT growth 1Y573.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y493.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.69%
OCF growth 3YN/A
OCF growth 5YN/A